Table 1.
Characteristics of 264 HIV-1 infected women by treatment arm
| Albendazole + praziquantel |
Praziquantel only |
Albendazole only |
Placebo | |
|---|---|---|---|---|
| Number HIV infected women enrolled | 67 | 54 | 64 | 79 |
| Age in years | ||||
| <20 | 9 (13%) | 8 (15%) | 9 (14%) | 10 (13%) |
| 20-24 | 23 (34%) | 21 (39%) | 18 (28%) | 29 (37%) |
| 25-29 | 18 (27%) | 15 (28%) | 23 (36%) | 22 (28%) |
| ≥30 | 17 (25%) | 10 (19%) | 15 (22%) | 18 (23%) |
| Education | ||||
| None | 9 (13%) | 1 (2%) | 3 (5%) | 5 (6%) |
| Primary | 39 (58%) | 33 (61%) | 36 (56%) | 45 (57%) |
| Secondary | 12 (18%) | 16 (30%) | 22 (34%) | 26 (33%) |
| Tertiary | 7 (10%) | 4 (7%) | 3 (5%) | 3 (4%) |
| Marital status | ||||
| Married | 49 (73%) | 46 (85%) | 52 (81%) | 63 (80%) |
| Single | 12 (18%) | 5 (9%) | 8 (13%) | 9 (11%) |
| Widowed/divorced/separated | 6 (9%) | 3 (6%) | 5 (6%) | 7 (9%) |
| Gravidity | ||||
| 1 | 9 (13%) | 10 (19%) | 14 (22%) | 11 (14%) |
| 2-4 | 41 (61%) | 30 (56%) | 33 (52%) | 50 (63%) |
| ≥5 | 17 (25%) | 14 (26%) | 17 (27%) | 18 (23%) |
| Helminth infections | ||||
| Hookworm | 20 (30%) | 24 (44%) | 25 (39%) | 33 (42%) |
| S. mansoni | 13 (19%) | 8 (15%) | 14 (22%) | 13 (16%) |
| M. perstans | 13 (19%) | 14 (26%) | 15 (23%) | 20 (25%) |
| S. stercoralis (1mv) | 10 (15%) | 8 (15%) | 4 (6%) | 6 (8%) |
| T. trichiura | 6 (9%) | 4 (8%) | 7 (11%) | 7 (9%) |
| A. lumbricoides | 1 (1%) | 0 (0%) | 3 (5%) | 2 (3%) |
| Any helminth | 42 (63%) | 35 (65%) | 44 (69%) | 54 (69%) |
| Malaria parasitaemia (3 mv) a | ||||
| Positive | 7 (11%) | 8 (15%) | 8 (13%) | 22 (28%) |
| CD4 count | ||||
| <300 | 13 (19%) | 10 (19%) | 9 (14%) | 14 (18%) |
| 300-499 | 25 (37%) | 11 (20%) | 16 (25%) | 19 (24%) |
| >=500 | 18 (27%) | 19 (35%) | 26 (41%) | 30 (38%) |
| Not done | 11 (16%) | 14 (26%) | 13 (20%) | 16 (20%) |
| HIV-1 log10 load at enrolment | ||||
| Mean (SD) | 4.00 (0.91) | 4.11 (0.96) | 3.96 (0.85) | 4.27 (0.96) |
| Assay used to measure HIV load at baseline | ||||
| Bayer | 60 (90%) | 49 (91%) | 60 (94%) | 68 (86%) |
| Roche | 7 (10%) | 5 (9%) | 4 (6%) | 11 (14%) |
| Assay used to measure HIV load at six weeks post-treatment (166 samples tested) | ||||
| Bayer | 16 (40%) | 11 (34%) | 19 (44%) | 14 (27%) |
| Roche | 24 (60%) | 21 (66%) | 24 (56%) | 37 (73%) |
| Assay used to measure HIV load at delivery (234 samples tested) | ||||
| Bayer | 59 (98%) | 46 (100%) | 56 (97%) | 66 (94%) |
| Roche | 1 (2%) | 0 (0%) | 2 (3%) | 4 (6%) |
a
mv=missing values